Skip to main content
Brazilian Journal of Microbiology logoLink to Brazilian Journal of Microbiology
. 2012 Jun 1;43(4):1376–1384. doi: 10.1590/S1517-838220120004000019

In vitro antagonistic growth effects of Lactobacillus fermentum and lactobacillus salivarius and their fermentative broth on periodontal pathogens

Ling-Ju Chen 1, Hsiu-Ting Tsai 2, Wei-Jen Chen 3, Chu-Yang Hsieh 3, Pi-Chieh Wang 4, Chung-Shih Chen 5, Lina Wang 6, Chi-Chiang Yang 6,7,*
PMCID: PMC3769017  PMID: 24031966

Abstract

As lactobacilli possess an antagonistic growth property, these bacteria may be beneficial as bioprotective agents for infection control. However, whether the antagonistic growth effects are attributed to the lactobacilli themselves or their fermentative broth remains unclear. The antagonistic growth effects of Lactobacillus salivarius and Lactobacillus fermentum as well as their fermentative broth were thus tested using both disc agar diffusion test and broth dilution method, and their effects on periodontal pathogens, including Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis in vitro at different concentrations and for different time periods were also compared. Both Lactobacillus salivarius and Lactobacillus fermentum and their concentrated fermentative broth were shown to inhibit significantly the growth of Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis, although different inhibitory effects were observed for different pathogens. The higher the counts of lactobacilli and the higher the folds of concentrated fermentative broth, the stronger the inhibitory effects are observed. The inhibitory effect is demonstrated to be dose-dependent. Moreover, for the lactobacilli themselves, Lactobacillus fermentum showed stronger inhibitory effects than Lactobacillus salivarius. However, the fermentative broth of Lactobacillus fermentum showed weaker inhibitory effects than that of Lactobacillus salivarius. These data suggested that lactobacilli and their fermentative broth exhibit antagonistic growth activity, and consumption of probiotics or their broth containing lactobacilli may benefit oral health.

Keywords: Lactobacillus fermentum, Lactobacillus salivarius, Streptococcus mutans, Streptococcus sanguis, Porphyromonas gingivalis, periodontitis

INTRODUCTION

Periodontitis, one of the most prevalent oral diseases, is associated with the imbalance of indigenous microbiota (10), and subsequently induces overgrowth of periodontal pathogens including Streptococcus mutans, Streptococcus sanguis, andPorphyromonas gingivalis (10, 21, 25, 27, 28). To treat periodontitis, antibiotic therapy is usually administered along with traditional treatments, including scaling and root planning, for reducing the bacteria and preventing the recurrence of infection (7, 12). However, some individuals with periodontal disease respond neither to the treatment of scaling and root planning alone nor to treatment in combination with antibiotic therapy (32). Moreover, antibiotic resistance poses further problems, thus limiting the application of antibiotic therapy in the treatment of periodontitis (30, 31). Therefore, additional strategies on the use of probiotics in prevention and treatment of periodontal disease are strongly recommended.

Lactobacilli colonize naturally in the vagina and digestive tract, and possess antagonistic growth properties that offer protection from invasive pathogens (20). Genitourinary infections lead to a shift in the local flora from a predominance of lactobacilli to coliform uropathogens. Use of lactobacillus-containing probiotics to restore commensal vaginal flora has been proposed for the treatment and prophylaxis of bacterial urogenital infections (6). Among lactobacilli genera,Lactobacillus salivarius and Lactobacillus fermentum are two of the most prevalent species in human saliva (9, 10). The genera belonging to this group can produce organic acids, such as lactic acid and acetic acid from carbohydrate fermentation, which can interfere with the growth of surrounding microorganisms and hydrogen peroxide which are antimicrobial substances (14). As lactobacilli possess an antagonistic growth property, these bacteria may be beneficial as bioprotective agents for infection control. Non-antibiotic therapy (25) has recently been applied in the treatment of periodontal diseases and has resolved the problem of antibiotic resistance (30, 31). However, whether the antagonistic growth activity is attributed to the lactobacilli themselves or their fermentative broth remains unclear.

The aim of this study was to determine the antagonistic growth effects of Lactobacillus salivarius and Lactobacillus fermentum as well as their fermentative broth on growth inhibition of periodontal pathogens, including Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis. In the present study, the antagonistic growth effects of these two species of lactobacilli and their fermentative broth were tested using both disc agar diffusion test and broth dilution method. In addition, their effects on the three well-known periodontal pathogensin vitro at different concentrations and for different durations were also compared.

MATERIALS AND METHODS

Bacterial strains and culture conditions

Bacterial strains, including Streptococcus mutans (ATCC25175), Streptococcus sanguis (ATCC49295), andPorphyromonas gingivalis (ATCC33277) were purchased from Bioresource Collection and Research Center, Food Industry Research and Development Institute (Hsinchu, Taiwan, R.O.C.) and cultured according to the manufacturer’s instructions. Streptococcus mutans was grown on tryptic soy broth (DIFCO 0369) with 5% defibrinated sheep blood at 37°C under aerobic conditions. Streptococcus sanguis was grown on brain heart infusion (BHI) broth (DIFCO 0418) at 37°C under aerobic conditions.Porphyromonas gingivalis was grown on BHI-T-C medium at 37°C under anaerobic conditions. In a screening of our collection of 22 species of lactobacilli, Lactobacillus salivarius and Lactobacillus fermentum were the best two lactobacilli that demonstrated antagonistic growth properties. Both lactobacillus species, Lactobacillus fermentum (strain SG-A95) and Lactobacillus salivarius (strain SG-M6), provided by Syngen Biotech Co. Ltd. (Tainan, Taiwan) were cultured in Mann Rogosa Sharp (MRS) broth at 37°C under anaerobic conditions. 5 x 107 cfu of Lactobacillus fermentum and Lactobacillus salivarius were cultured in 20 ml MRS for 24 hours (hr) to prepare the fermented broth. The fermented broth of Lactobacillus salivarius and Lactobacillus fermentum were then centrifuged at 10,000 rpm for 10 minutes (min) to remove the cell pellet and concentrated by a rotary vacuum evaporator at 60°C as the concentrated fermentative broth. In order to reduce the salts present in the concentrated fermentative broth, dialysis with a membrane (Spectra/Por®Dialysis Membrane; MWCO:3500, Spectrum Laboratories Inc, CA, USA) was performed for 48 hr before subsequent experiments. The fermentative broth and the lactobacilli themselves were stored at -80°C until required (Flowchart 1).

Flowchart 1.

Flowchart 1

Summarizing the preparation steps involved in the present study.

Disc agar diffusion test

Paper discs infused with different concentrations of fermented MRS were placed on the surface of agar plates inoculated with the three different bacteria mentioned above, and incubated at 37°C for 24 hr in triplicate. Distilled water and 250 mg/mL of tetracycline were used as negative and positive controls, respectively. Each sample was tested by three repeated analyses. The diameter of the inhibition zone around the disc was measured (mm). The diameter of the inhibition zone for the negative control (dist. water) was 6 mm.

Broth dilution method

One milliliter of Lactobacillus salivarius or Lactobacillus fermentum suspension stock at counts of 5 x 107 cfu/ml, 5 x 108 cfu/ml or 5 x 109 cfu/ml; or 2-fold or 4-fold concentrated fermented broth of Lactobacillus salivarius or Lactobacillus fermentum was co-cultured with 1 ml of Streptococcus mutans, Streptococcus sanguis, or Porphyromonas gingivalis at a count of 5 x 107 cfu/ml under periodontal bacteria’s culture conditions as described above for different durations. The numbers of periodontal bacterial strains, i.e. Streptococcus mutans, Streptococcus sanguis, andPorphyromonas gingivalis, were counted at each time point and compared with unused MRS co-cultured with bacterial strains (negative controls). The number of bacterial strains was calculated by plating on agar plates as described above. Each sample was tested by three repeated analyses. The percentage of inhibitory was calculated as 100% - [(Test group ÷ Control) x 100%].

Statistical analysis

Experimental results are presented as mean values. The Kruskal-Wallis test was employed to detect the difference in in growth inhibition of periodontal pathogens among three or more than three groups, and Scheffe correction was performed to check statistically significant difference between groups. P value of less than 0.01 was considered significant. The data were analyzed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) statistical software.

RESULTS

Disc agar diffusion test

The growth inhibitory effects of the fermentative broth of Lactobacillus fermentum and Lactobacillus salivarius on Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis were demonstrated by disc agar diffusion test. The inhibitory diameters of different concentrations of Lactobacillus fermentum and Lactobacillus salivarius fermentative broth were shown in Table 1. Significant inhibitory effects of the fermentative broth of bothLactobacillus fermentum and Lactobacillus salivarius at different concentrations were demonstrated except for that at 1-fold concentration.

Table 1.

Growth inhibitory effects of fermentative broth of Lactobacillus fermentum and Lactobacillus salivarius on Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis obtained by disc agar diffusion test (n= 3).

Product Streptococcus mutans Streptococcus sanguis Porphyromonas gingivialis
LFP 1-fold 6.0±0.0 6.0±0.0 6.2±0.2
LFP 2-fold 7.6±0.9 7.7±1.0 9.2±1.0
LFP 4-fold 13.2±1.2 12.4±1.2 9.7±0.6
LSP 1-fold 6.1±0.0 6.0±0.0 6.6±0.5
LSP 2-fold 9±1.0 9±1.0 12±1.0
LSP 4-fold 13±1.0 16±1.0 14±1.0
Tetracycline 29.7±2.0 25.9±1.2 33.4±2.2
Distilled water 6.0±0.0 6.0±0.0 6.0±0.0

LFP: Lactobacillus fermentum fermentative broth

LSP: Lactobacillus salivarius fermentative broth

Broth dilution method

One milliliter of Lactobacillus fermentum or Lactobacillus salivarius suspension stock at counts of 5 x 107 cfu/ml, 5 x 108 cfu/ml, or 5 x 109 cfu/ml was co-cultured with 1 ml of 5 x 107 cfu/mlStreptococcus mutans, Streptococcus sanguis, or Porphyromonas gingivalis under these periodontal bacteria’s culture conditions for different durations. Growth titers of Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis counted at different time points were used as negative controls for comparison (Fig. 1). The results are shown on Fig. 2. Significant growth inhibitory effects (p < 0.01) were observed when lactobacilli were co-cultured with the pathogenic bacteria at a 1:1 ratio (5 x 107 cfu/ml). The higher the count (5 x 108 cfu/ml or 5 x 109 cfu/ml) of Lactobacillus fermentum or Lactobacillus salivarius treated, the higher the growth inhibitory effects (p < 0.01) on Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis were observed (Fig. 2). Moreover, lactobacilli at a higher ratio (100:1) exhibited stronger growth inhibitory effects on the three pathogenic bacteria tested than those at a lower ratio (10:1 or 1:1). For example, growth of Streptococcus mutans was completely inhibited after 48 hr of 1- (5 x 107 cfu/ml), 10- (5 x 108 cfu/ml) or 100-fold (5 x 109 cfu/ml) Lactobacillus fermentum treatment.

Figure 1.

Figure 1

Growth curves of Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis tested at different time points and used as negative controls for test on inhibitory effects (n= 3).

Figure 2.

Figure 2

Figure 2

Growth inhibitory percentages of different counts of (a) Lactobacillus fermentum or (b) Lactobacillus salivarius on 5 x 107 cfu/mlStreptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis at different time points (n= 3).

For Streptococcus sanguis, significant growth inhibition effects (p < 0.01) by 1- (5 x 107 cfu/ml), 10- (5 x 108 cfu/ml), and 100-fold (5 x 109 cfu/ml) of Lactobacillus fermentum or Lactobacillus salivarius treatment were also found (Fig. 2). For example, the growth of Streptococcus sanguis was completely inhibited after 14 hr of 1- and10-fold or 10 hr of 100-fold Lactobacillus fermentum treatment, respectively.

For Porphyromonas gingivalis, when co-cultured with 5 x 107 cfu/ml, 5 x 108 cfu/ml or 5 x 109 cfu/mlLactobacillus fermentum or Lactobacillus salivarius, significant growth inhibitory effects (p < 0.01) were also demonstrated (Fig. 2). For example, the growth of Porphyromonas gingivalis was completely inhibited after 14 hr of 1-fold, 8 hr of 10-fold or 6 hr of 100-fold Lactobacillus fermentum treatment, respectively. For the three oral pathogens tested, Lactobacillus fermentum showed stronger inhibitory effects than Lactobacillus salivarius.

Since 1-fold fermentative broth of Lactobacillus fermentum and Lactobacillus salivarius did not show significant inhibitory effects by disc agar diffusion test, 2- and 4-fold concentrated fermentative broth were thus used for test. The broth dilution method demonstrated significant growth inhibitory effects of the concentrated fermentative broth of Lactobacillus fermentum and Lactobacillus salivarius on periodontal pathogens (Fig. 3). Both 2- and 4-fold concentrated fermentative broth of Lactobacillus fermentum and Lactobacillus salivarius inhibited significantly the growth of periodontal pathogens, including Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis. However, the fermentative broth of Lactobacillus fermentum showed weaker inhibitory effects than that of Lactobacillus salivarius.

Figure 3.

Figure 3

Figure 3

Growth inhibitory effect of different folds of concentrated (a) Lactobacillus fermentum or (b) Lactobacillus salivarius fermentative broth on 5 x 107 cfu/mlStreptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis at different time points (n= 3).

DISCUSSION

Probiotics are defined as microorganisms that generally confer a health benefit on humans (5, 8). Lactobacilli, which have been consumed daily by millions of people around the world for perceived health benefits, have been regarded as safe. Intestinal lactobacilli have been successfully used as probiotics to treat gastrointestinal disorders, but only limited data on the probiotic properties of oral lactobacilli for combating oral diseases are available. The use of probiotics in clinical trials should be accompanied by knowledge of the antagonistic growth susceptibilities of the organism used (24). In the present study, lactobacilli and their fermentative broth were tested in vitro for their potential probiotic properties for oral health. Both Lactobacillus salivarius and Lactobacillus fermentum and their fermentative broth were shown to inhibit the growth of three periodontal pathogens, i.e.,Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis, although different inhibitory effects were observed for different pathogens. Moreover, the higher the counts of lactobacilli and the higher the folds of concentrated fermentative broth, the stronger the inhibitory effects were, indicating that the inhibitory effect was dose-dependent.

In the lactobacilli genera, it was reported that strains of Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus paracasei, andLactobacillus rhamnosus expressed high antimicrobial activity (11). Lactobacillus salivarius CECT5713 has recently been shown not only to be the best for in vitro antibacterial activity, but has also been found to possess the highest protective effect against a Salmonella strain in the murine infection model (19). Lactobacillus salivarius CELA2 (a bacteriocin-producing strain) was shown to display the highest probiotic potential in the gastrointestinal tract (13). Lactobacillus fermentum strain L23 and Lactobacillus rhamnosus strain L60 were suggested for prevention and treatment of urogenital infections in women, in view of their probiotic properties and production of bacteriocins (23). Short-term consumption of cheese containing Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC705 has been shown to reduce the risk of Streptococcus mutans in young adults, although their long-term effects remain unclear (1). Application of Lactobacillus reuteri was found to result in reduced gum bleeding and gingivitis. Oral lactobacilli flora has also been shown to inhibit the growth of Porphyromonas gingivalis and Prevotella intermedia (10). Taken together, our data are consistent with other findings indicating that lactobacilli and their fermentative broth exhibit antagonistic growth activity and consumption of probiotics or their broth containing lactobacilli can prevent or treat periodontal disease (2, 17, 18). These results suggest a potential for the two lactobacilli species and their fermented broths to be used as probiotics and functional products, respectively for oral health.

Moreover, for the lactobacilli themselves, Lactobacillus fermentum showed stronger inhibitory effects than Lactobacillus salivarius. However, the fermentative broth of Lactobacillus fermentum showed weaker inhibitory effects than that of Lactobacillus salivarius. The mechanisms of probiotic action in the mouth are supposed to be similar to that observed in gastrointestinal tracts (15). Nevertheless, data on oral probiotics are yet insufficient. Probiotics has been used as passive local immunization vehicles to improve oral immune response and to prevent against oral diseases (2, 29). Recent reports on the search of antimicrobial protein/compounds produced by lactic acid bacteria have been increasing (4, 16, 22, 26). Furthermore, probiotics produce organic acids including lactic, acetic and formic acids, which lower pH and oxidation-reduction potential and may suppress harmful organisms. It is possible that the mechanism of action is attributed to the organic acids produced by the probiotics and present in the fermentative broth. However, in view of the difference in antibacterial potential between the two lactobacilli and their fermentative broth, such possibility was rather low. It was thus suggested the two lactobacilli species themselves may undergo different mechanisms to exhibit inhibitory effects on oral pathogens, e.g. the lacotobacilli may compete with oral pathogens for growth nutrients or growth space, which is different from the replication inhibition underwent by the antimicrobial protein/compounds in the fermentative broth. Further investigation is needed to elucidate this assumption.

In conclusion, we have demonstrated through in vitro growth inhibitory test that Lactobacillus fermentum and Lactobacillus salivarius and their concentrated fermentative broth inhibit significantly periodontal pathogens, including Streptococcus mutans, Streptococcus sanguis, and Porphyromonas gingivalis in a dose-dependent manner. Consumption of probiotics or their broth containing lactobacilli may benefit oral health. However, further and extensive researches including human studies are needed.

ACKNOWLEDGEMENTS

This study was funded by grants from the Chung Shan Medical University (CSMU 98-OM-A-169 and 99-CSMU-PGH-02).

REFERENCES

  • 1.Ahola A.J., Yli-Knuuttila H., Suomalainen T., Poussa T., Ahlstrom A., Meurman J.H., Korpela R. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Arch. Oral Biol. 2002;47:799–804. doi: 10.1016/s0003-9969(02)00112-7. [DOI] [PubMed] [Google Scholar]
  • 2.Çglar E., Kargul B., Tanboga I. Bacteriotherapy and probiotics' role on oral health. Oral Dis. 2005;11:131–137. doi: 10.1111/j.1601-0825.2005.01109.x. [DOI] [PubMed] [Google Scholar]
  • 3.Çaglar E., Kuscu O.O., Kuvvetli S.S., Cildir S.K.,  Sandalli N., Twetman S. Short-term effect of ice-cream containing Bifidobacterium lactis Bb-12 on the number of salivary mutans streptococci and lactobacilli. Acta Odontol. Scand. 2008;66:154–158. doi: 10.1080/00016350802089467. [DOI] [PubMed] [Google Scholar]
  • 4.Clare D.A., Zheng Z., Hassan H.M., Swaisgood H.E., Catignani G.L. Antimicrobial properties of milkfat globule membrane fractions. J. Food Prot. 2008;71:126–133. doi: 10.4315/0362-028x-71.1.126. [DOI] [PubMed] [Google Scholar]
  • 5.de Vrese M., Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 2008;111:1–66. doi: 10.1007/10_2008_097. [DOI] [PubMed] [Google Scholar]
  • 6.Dover S.E., Aroutcheva A.A., Faro S., Chikindas M.L. Safety study of an antimicrobial peptide lactocin 160, produced by the vaginal Lactobacillus rhamnosus. Infect. Dis. Obstet. Gynecol. 2007;2007:78248. doi: 10.1155/2007/78248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Greenstein G., Polson A. The role of local drug delivery in the management of periodontal diseases: a comprehensive review. J. Periodontol. 1998;69:507–520. doi: 10.1902/jop.1998.69.5.507. [DOI] [PubMed] [Google Scholar]
  • 8.Gupta V., Garg R. Probiotics. Indian J. Med. Microbiol. 2009;27:202–209. doi: 10.4103/0255-0857.53201. [DOI] [PubMed] [Google Scholar]
  • 9.Hojo K., Mizoguchi C., Taketomo N., Ohshima T., Gomi K., Arai T., Maeda N. Distribution of salivary Lactobacillus and Bifidobacterium species in periodontal health and disease. Biosci., Biotechnol., Biochem. 2007;71:152–157. doi: 10.1271/bbb.60420. [DOI] [PubMed] [Google Scholar]
  • 10.Koll-Klais P., Mandar R., Leibur E., Marcotte H., Hammarstrom L., Mikelsaar M. Oral lactobacilli in chronic periodontitis and periodontal health: species composition and antimicrobial activity. Oral Microbiol. Immunol. 2005;20:354–361. doi: 10.1111/j.1399-302X.2005.00239.x. [DOI] [PubMed] [Google Scholar]
  • 11.Koll P., Mandar R., Marcotte H., Leibur E., Mikelsaar M., Hammarstrom L. Characterization of oral lactobacilli as potential probiotics for oral health. Oral Microbiol. Immunol. 2008;23:139–147. doi: 10.1111/j.1399-302X.2007.00402.x. [DOI] [PubMed] [Google Scholar]
  • 12.Mariotti A., Monroe P.J. Pharmacologic management of periodontal diseases using systemically administered agents. Dent. Clin. North Am. 1998;42:245–262. [PubMed] [Google Scholar]
  • 13.Martin R., Delgado S., Maldonado A., Jimenez E., Olivares M., Fernandez L., Sobrino O.J., Rodriguez J.M. Isolation of lactobacilli from sow milk and evaluation of their probiotic potential. J. Dairy Res. 2009;76:418–425. doi: 10.1017/S0022029909990124. [DOI] [PubMed] [Google Scholar]
  • 14.McGroarty J.A., Tomeczek L., Pond D.G., Reid G., Bruce A.W. Hydrogen peroxide production by Lactobacillus species: correlation with susceptibility to the spermicidal compound nonoxynol-9. J. Infect. Dis. 1992;165:1142–1144. doi: 10.1093/infdis/165.6.1142. [DOI] [PubMed] [Google Scholar]
  • 15.Meurman J.H., Stamatova I. Probiotics: contributions to oral health. Oral Diseases. 2007;13:443–451. doi: 10.1111/j.1601-0825.2007.01386.x. [DOI] [PubMed] [Google Scholar]
  • 16.Millette M., Dupont C., Archambault D., Lacroix M. Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates. J. Appl. Microbiol. 2007;102:274–282. doi: 10.1111/j.1365-2672.2006.03044.x. [DOI] [PubMed] [Google Scholar]
  • 17.Nase L., Hatakka K., Savilahti E., Saxelin M., Ponka A., Poussa T., Korpela R., Meurman J.H. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35:412–420. doi: 10.1159/000047484. [DOI] [PubMed] [Google Scholar]
  • 18.Nikawa H., Makihira S., Fukushima H., Nishimura H., Ozaki Y., Ishida K., Darmawan S., Hamada T., Hara K., Matsumoto A., Takemoto T., Aimi R. Lactobacillus reuteri in bovine milk fermented decreases the oral carriage of mutans streptococci. Int. J. Food Microbiol. 2004;95:219–223. doi: 10.1016/j.ijfoodmicro.2004.03.006. [DOI] [PubMed] [Google Scholar]
  • 19.Olivares M., Diaz-Ropero M.P., Martin R., Rodriguez J.M., Xaus J. Antimicrobial potential of four Lactobacillus strains isolated from breast milk. J. Appl. Microbiol. 2006;101:72–79. doi: 10.1111/j.1365-2672.2006.02981.x. [DOI] [PubMed] [Google Scholar]
  • 20.Orrhage K., Nord C.E. Bifidobacteria and lactobacilli in human health. Drugs Exp. Clin. Res. 2000;26:95–111. [PubMed] [Google Scholar]
  • 21.Ouhara K., Komatsuzawa H., Yamada S., Shiba H., Fujiwara T., Ohara M., Sayama K., Hashimoto K., Kurihara H., Sugai M. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, □-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. 2005;55:888–896. doi: 10.1093/jac/dki103. [DOI] [PubMed] [Google Scholar]
  • 22.Rojo-Bezares B., Saenz Y., Zarazaga M., Torres C., Ruiz-Larrea F. Antimicrobial activity of nisin against Oenococcus oeni and other wine bacteria. Int. J. Food Microbiol. 2007;116:32–36. doi: 10.1016/j.ijfoodmicro.2006.12.020. [DOI] [PubMed] [Google Scholar]
  • 23.Ruiz F.O., Gerbaldo G., Asurmendi P., Pascual L.M., Giordano W., Barberis I.L. Antimicrobial activity, inhibition of urogenital pathogens, and synergistic interactions between lactobacillus strains. Curr. Microbiol. 2009;59:497–501. doi: 10.1007/s00284-009-9465-0. [DOI] [PubMed] [Google Scholar]
  • 24.Snydman D.R. The safety of probiotics. Clin. Infect. Dis. 2008;46(Suppl 2):S104–11. S144–51. doi: 10.1086/523331. discussion. [DOI] [PubMed] [Google Scholar]
  • 25.Spacciapoli P., Buxton D., Rothstein D., Friden P. Antimicrobial activity of silver nitrate against periodontal pathogens. J. Periodontal Res. 2001;36:108–113. doi: 10.1034/j.1600-0765.2001.360207.x. [DOI] [PubMed] [Google Scholar]
  • 26.Sutyak K.E., Wirawan R.E., Aroutcheva A.A., Chikindas M.L. Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens. J. Appl. Microbiol. 2008;104:1067–1074. doi: 10.1111/j.1365-2672.2007.03626.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Taubman M.A., Han X., Larosa K.B., Socransky S.S., Smith D.J. Periodontal bacterial DNA suppresses the immune response to mutans streptococcal glucosyltransferase. Infect. Immun. 2007;75:4088–4096. doi: 10.1128/IAI.00623-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Thiha K., Takeuchi Y., Umeda M., Huang Y., Ohnishi M., Ishikawa I. Identification of periodontopathic bacteria in gingival tissue of Japanese periodontitis patients. Oral Microbiol. Immunol. 2007;22:201–207. doi: 10.1111/j.1399-302X.2007.00354.x. [DOI] [PubMed] [Google Scholar]
  • 29.Vancikova Z., Lodinova-Zadnikova R., Radl J., Tlaskalová-Hogenová H. The early postnatal development of salivary antibody and immunoglobulin response in children orally colonized with a nonpathogenic, probiotic strain of E. coli. Folia Microbiol. (Praha) 2003;48:281–287. doi: 10.1007/BF02930970. [DOI] [PubMed] [Google Scholar]
  • 30.van Winkelhoff A.J., Herrera D., Winkel E.G., Dellemijn-Kippuw N., Vandenbroucke-Grauls C.M., Sanz M. Antibiotic resistance in the subgingival microflora in patients with adult periodontitis. A comparative survey between Spain and the Netherlands. Ned Tijdschr Tandheelkd. 1999;106:290–294. [PubMed] [Google Scholar]
  • 31.van Winkelhoff A.J., Herrera Gonzales D., Winkel E.G., Dellemijn-Kippuw N., Vandenbroucke-Grauls C.M., Sanz M. Antimicrobial resistance in the subgingival microflora in patients with adult periodontitis. A comparison between the Netherlands and Spain. J. Clin. Periodontol. 2000;27:79–86. doi: 10.1034/j.1600-051x.2000.027002079.x. [DOI] [PubMed] [Google Scholar]
  • 32.Wasserman B., Hirschfeld L. The relationship of initial clinical parameters to the long-term response in 112 cases of periodontal disease. J. Clin. Periodontol. 1988;15:38–42. doi: 10.1111/j.1600-051x.1988.tb01552.x. [DOI] [PubMed] [Google Scholar]

Articles from Brazilian Journal of Microbiology are provided here courtesy of Brazilian Society of Microbiology

RESOURCES